Today: 8 February 2026
Subscribe
Browse Category

NASDAQ:BLTE News 11 December 2025 - 30 December 2025

Belite Bio stock swings to $170 and closes up nearly 7% as rally stays hot into year-end

Belite Bio stock swings to $170 and closes up nearly 7% as rally stays hot into year-end

NEW YORK, December 30, 2025, 05:26 ET — Premarket Belite Bio’s U.S.-listed shares were back in focus early Tuesday after the stock surged 6.7% in the prior session, swinging between $151.50 and $169.75 before ending at $165.29. Volume was 309,235 shares, above recent daily levels for the thinly traded biotech. StockAnalysis The move matters because Belite is trying to turn a rare-disease eye drug into a first-in-class launch, and the stock is now trading well above the $154 level at which it last sold new shares in a major December offering. In markets where liquidity thins out near year-end, sharp
30 December 2025
··
Belite Bio (NASDAQ: BLTE) Stock: DRAGON Trial Breakthrough, $350 Million Offering and Outlook After a 130% Rally

Belite Bio (NASDAQ: BLTE) Stock: DRAGON Trial Breakthrough, $350 Million Offering and Outlook After a 130% Rally

Belite Bio, Inc. (NASDAQ: BLTE) has turned into one of 2025’s most closely watched biotech stories. On the back of a pivotal Phase 3 win in Stargardt disease and a large equity raise, the small-cap ophthalmology specialist has seen its share price more than double this year and its market value climb into the multi‑billion‑dollar range.BioPharma Dive+1 As of the afternoon of December 11, 2025, Belite Bio stock is trading around $154 per share, up roughly 4–5% on the day and more than 130% year‑to‑date, giving the company a market capitalization of roughly $5–6 billion.Stock Titan+1 The rally has pushed
11 December 2025
·

Stock Market Today

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 08.02.2026

8 February 2026
LIVEMarkets rolling coverageStarted: February 8, 2026, 12:00 AM ESTUpdated: February 8, 2026, 12:38 AM EST Magna International (TSX:MG) Shares Show Mixed Performance; DCF Suggests Undervaluation February 8, 2026, 12:28 AM EST. Magna International (TSX:MG) closed at CA$73.80, reflecting a 6.0% gain over 7 days but a 5.6% decline over 30 days. The stock is down 1.6% year to date, up 40.3% over one year, yet down 11.5% over five years, giving a mixed performance picture. Analysts highlight shifting auto sector dynamics affecting investor sentiment. A Discounted Cash Flow (DCF) model estimates Magna's intrinsic value at CA$94.25 per share, implying a
Tower Semiconductor stock jumps again on Nvidia optics tie-up as earnings near

Tower Semiconductor stock jumps again on Nvidia optics tie-up as earnings near

8 February 2026
Tower Semiconductor shares rose 7.7% to $139.04 Friday after announcing a collaboration with Nvidia on AI data-center networking. The stock touched $141 intraday and gained another 1% after hours. Investors await Tower’s Feb. 11 earnings for details on its silicon photonics work. No financial terms or shipment timeline were disclosed.
Longsys Electronics stock heads into Monday after new guarantees; what 301308 investors watch next

Longsys Electronics stock heads into Monday after new guarantees; what 301308 investors watch next

8 February 2026
Longsys disclosed new guarantees for a 100 million yuan Hong Kong loan and a $9 million Brazil credit line, bringing its total approved guarantee quota to 11 billion yuan and outstanding guarantees to 5.81 billion yuan. The company said all guarantees are for consolidated subsidiaries and within approved limits. Shares closed at 288 yuan Friday, down 1.6%. China inflation and credit data are due this week.
MACOM stock price steadies near highs into Monday after earnings pop and fresh filings

MACOM stock price steadies near highs into Monday after earnings pop and fresh filings

8 February 2026
MACOM shares rose 3.5% to $235.87 Friday after the company reported fiscal Q1 revenue of $271.6 million and raised its full-year data center growth outlook to 35–40%. Fidelity’s FMR LLC disclosed a 10.7% stake, while shareholder Susan Ocampo filed to potentially sell up to 100,000 shares. Stifel raised its price target to $255. MACOM expects to repay $161 million in convertible notes in March.
Go toTop